HEP002 trial represents the world's first Phase IIb/III trial with a stem cell-based medicinal product for the treatment of urea cycle disorders patients. Mont-Saint-Guibert, Belgium, October 15, 2014 - Promethera Biosciences, a Belgian biotechnology company developing PrometheraA HepaStem, a cell-based therapy for the treatment of both orphan liver-based metabolic diseases and acquired liver diseases, today announces that Belgium has authorized the conduct of a trial designed to treat paediatric patients with urea cycle disorders in a Phase IIb/III study .
http://www.biospace.com/news_story.aspx?StoryID=350187&full=1
http://www.biospace.com/news_story.aspx?StoryID=350187&full=1
No comments:
Post a Comment